News Advicenne

Equities

ALDVI

FR0013296746

Real-time Euronext Paris Other stock markets 06:54:59 2024-04-23 am EDT			5-day change	1st Jan Change
1.72 ^EUR	+0.82%		+3.74%	-35.34%

Apr. 08	Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	Advicenne: ODD designation in cystinuria	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Advicenne : met à disposition son Document d’Enregistrement Universel 2023	Apr. 08	PU
Advicenne : 2023 Universal Registration Document made available	Apr. 08	PU
Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 07	CI
Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal®	Mar. 28	BU
Advicenne - FDA grants Orphan Drug Designation to ADV7103 for the treatment of cystinuria	Mar. 26	AQ
Advicenne : Inside Information / Other news releases	Mar. 25	PU
Advicenne: ODD designation in cystinuria	Mar. 25	CF
FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria.	Mar. 25	BU
Advicenne reports 2023 gross sales1 up 20% to EUR4.43 million	Jan. 24	AQ
Advicenne: share price hit after 2023 sales figures	Jan. 24	CF
Advicenne announces the results of its capital increase with preferential subscription rights	23-10-03	AQ
Advicenne : October 2, 2023 - Advicenne announces the results of its capital increase with preferential subscription rights	23-10-02	PU
Advicenne reports its First Half Financial results as of June 30, 2023 and updates on its activities	23-09-12	AQ
Advicenne Kicks Off Share Offering to Achieve Operational Breakeven	23-09-12	MT
Advicenne S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-10	CI
Advicenne : June 14, 2023 - Advicenne announces long-term results of the European clinical development program for ADV7103	23-06-14	PU
Advicenne : Inside Information / Other news releases	23-06-09	PU
Advicenne : Inside Information / News release on accounts, results	23-03-30	PU
Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Advicenne Wins Danish Marketing Approval for Distal Renal Tubular Acidosis Treatment Sibnayal	23-03-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Advicenne

Equities

ALDVI

FR0013296746

Summary

Filters